Medtronic Diabetes expands access to full-stack insulin delivery solutions with Medicare access and new FDA clearances

GALWAY, Ireland, Feb. 2, 2026 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced three significant U.S. milestones that expand access, choice, and flexibility for people living with type 1 and insulinrequiring type 2 diabetes. These milestones include Medicare access for the MiniMedâ"¢ 780G system paired with the Instinct sensor, made by Abbott, FDA clearance for the system's use with ultra rapidacting insulins, and clearance of the MiniMedâ"¢ 780G system for us ...